Journal
DIABETES & VASCULAR DISEASE RESEARCH
Volume 9, Issue 2, Pages 89-94Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/1479164112441477
Keywords
Cardiovascular risk; clinical trials; PPAR / agonists; therapeutic strategies
Funding
- Roche
Ask authors/readers for more resources
The disappointing results of glucose lowering studies have highlighted the ongoing need to develop new therapeutic strategies to reduce cardiovascular risk in patients with type 2 diabetes. The presence of a range of metabolic abnormalities in diabetic patients presents a number of potential targets for therapeutic intervention. While modulation of peroxisome proliferator activated receptors (PPARs) represents an attractive approach, the results of studies of pharmacological agonists have been variable. The findings of these studies and rationale for development of dual PPAR-alpha/gamma agonists will be reviewed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available